Document:

<PAGE>
                                                                   EXHIBIT 10.17

                                AGCO CORPORATION
                     SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN
<PAGE>

                               TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                                                   Page
 <S>               <C>                                                                                             <C>
 ARTICLE I                 DEFINITIONS ......................................................................        1
           1.1     ACCRUAL FACTOR ...........................................................................        1
           1.2     ACCRUED BENEFIT ..........................................................................        1
           1.3     ACTUARIAL EQUIVALENT .....................................................................        1
           1.4     ADMINISTRATIVE COMMITTEE .................................................................        1
           1.5     AFFILIATE.................................................................................        1
           1.6     BASE SALARY...............................................................................        1
           1.7     BENEFIT COMMENCEMENT DATE ................................................................        2
           1.8     BOARD.....................................................................................        2
           1.9     CHANGE IN CONTROL.........................................................................        2
           1.10    CODE......................................................................................        2
           1.11    COMPANY...................................................................................        2
           1.12    DEATH BENEFIT.............................................................................        2
           1.13    EARLY RETIREMENT AGE .....................................................................        2
           1.14    EARLY RETIREMENT BENEFIT . ...............................................................        2
           1.15    EFFECTIVE DATE ...........................................................................        2
           1.16    ELIGIBLE EMPLOYEE ........................................................................        3
           1.17    EMPLOYMENT COMMENCEMENT DATE .............................................................        3
           1.18    ERISA.....................................................................................        3
           1.19    FINAL EARNINGS............................................................................        3
           1.20    JOINT AND 50% SURVIVOR ANNUITY............................................................        3
           1.21    NORMAL RETIREMENT AGE.....................................................................        3
           1.22    NORMAL RETIREMENT BENEFIT.................................................................        3
           1.23    PARTICIPANT...............................................................................        3
           1.24    PARTICIPATING COMPANY.....................................................................        3
           1.25    PLAN......................................................................................        3
           1.26    PLAN YEAR.................................................................................        3
           1.27    SAVINGS PLAN BENEFIT .....................................................................        3
           1.28    SOCIAL SECURITY BENEFIT...................................................................        4
           1.29    SURVIVING SPOUSE .........................................................................        4
           1.30    TRUST OR TRUST AGREEMENT..................................................................        4
           1.31    TRUSTEE...................................................................................        4
           1.32    TRUST FUND................................................................................        4
           1.33    YEARS OF CREDITED SERVICE.................................................................        4
 ARTICLE II                ELIGIBILITY ......................................................................        5
           2.1     SELECTION OF PARTICIPANTS ................................................................        5
           2.2     REMOVAL FROM ACTIVE PARTICIPATION ........................................................        5
 ARTICLE III               BENEFITS..........................................................................        6
           3.1  .............................................................................................        6
           BENEFIT AMOUNT....................................................................................        6
</TABLE>

<PAGE>

<TABLE>
<CAPTION>
                                                                                                                   Page
 <S>               <C>                                                                                             <C>
                   (A)     NORMAL RETIREMENT BENEFIT.........................................................        6
                   (B)     EARLY RETIREMENT BENEFIT .........................................................        6
                   (C)     TERMINATION BEFORE EARLY RETIREMENT DATE .........................................        6
                   PAYMENT OF BENEFIT .......................................................................        6
                   (A)     COMMENCEMENT AND TIMING ..........................................................        6
                   (B)     FORM OF PAYMENT FOR RETIREMENT BENEFIT ...........................................        6
           3.3     CHANGE IN CONTROL.........................................................................        7
           3.4     DEATH BENEFIT.............................................................................        7

 ARTICLE IV                CLAIMS............................................................................        8
           4.1     CLAIMS....................................................................................        8
                   (A)     INITIAL CLAIM ....................................................................        8
                   (B)     APPEAL............................................................................        8
                   (C)     SATISFACTION OF CLAIMS............................................................        8
 ARTICLE V                 SOURCE OF FUNDS; TRUST............................................................        9
           5.1     SOURCE OF FUNDS ..........................................................................        9

           5.2     TRUST.....................................................................................        9
 ARTICLE VI                ADMINISTRATIVE COMMITTEE..........................................................       10
           6.1     ACTION....................................................................................       10
           6.2     RIGHTS AND DUTIES.........................................................................       10
           6.3     COMPENSATION, INDEMNITY AND LIABILITY.....................................................       11
           6.4     TAXES.....................................................................................       11
ARTICLE VII                AMENDMENT AND TERMINATION.........................................................       12
           7.1     AMENDMENTS................................................................................       12
           7.2     TERMINATION OF PLAN.......................................................................       12
ARTICLE VIII               MISCELLANEOUS.....................................................................       13
           8.1     TAXATION..................................................................................       13
           8.2     NO EMPLOYMENT CONTRACT ...................................................................       13
           8.3     HEADINGS..................................................................................       13
           8.4     GENDER AND NUMBER.........................................................................       13
           8.5     ASSIGNMENT OF BENEFITS....................................................................       13
           8.6     LEGALLY INCOMPETENT.......................................................................       13
           8.7     GOVERNING LAW.............................................................................       14
 SCHEDULE A                PARTICIPATING COMPANIES ..........................................................       15
 SCHEDULE B                PARTICIPANTS .....................................................................       16
</TABLE>

                                       ii
<PAGE>

                                AGCO CORPORATION
                     SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN

         Effective as of the 1st day of April, 2000, AGCO Corporation, a
corporation duly organized and existing under the laws of the State of Delaware
(the "Company"), hereby adopts the AGCO Corporation Supplemental Executive
Retirement Plan (the "Plan").

                             BACKGROUND AND PURPOSE

         A.       GENERAL PURPOSE. The primary purpose of the Plan is to provide
additional retirement income to a select group of management personnel of the
Company and its affiliates that adopt the Plan as participating companies.

         B.       TYPE OF PLAN. The Plan constitutes an unfunded, nonqualified
deferred compensation plan that benefits certain designated employees who are
within a select group of key management or highly compensated employees.

                             STATEMENT OF AGREEMENT

         To establish the Plan with the purposes and goals as hereinabove
described, the Company hereby sets forth the terms and provisions as follows:
<PAGE>

                                    ARTICLE I
                                   DEFINITIONS

          For purposes of the Plan; the following terms, when used with an
initial capital letter, shall have the meaning set forth below unless a
different meaning plainly is required by the context.

         1.1      ACCRUAL FACTOR shall mean, with respect to a Participant, the
annual factor used to determine the Participant's Accrued Benefit, which is
equal to the product of (i) 3% multiplied by (ii) a fraction, the numerator of
which is 20 and the denominator of which is the number of full and partial
12-month periods between (i) the later of his Employment Commencement Date or
June 20, 1990, and (ii) the date on which he will attain his Normal Retirement
Age. In no event shall a Participant's Accrual Factor exceed 3%.

         1.2      ACCRUED BENEFIT shall mean, with respect to a Participant and
as of any date it is determined, an annual amount, payable for the life of the
Participant up to a maximum of 10 years, which is equal to (i) the Participant's
Final Earnings, multiplied by (ii) the Participant's Years of Credited Service,
multiplied by (iii) the Participant's Accrual Factor, and reduced by (iv) the
Participant's Social Security Benefit and Savings Plan Benefit; provided,
however, that the maximum Accrued Benefit attainable hereunder shall be equal to
60% of the Participant's Final Earnings, subject to reduction by the
Participant's Social Security Benefit and Savings Plan Benefit.

         1.3      ACTUARIAL EQUIVALENT shall mean an amount of equivalent value
based on the applicable mortality rate in effect under the GAM 1983 mortality
table and an effective annual interest rate of 7% compounded annually.

         1.4      ADMINISTRATIVE COMMITTEE shall mean a committee appointed by
the Board, which shall act on behalf of the Company to administer the Plan. From
time to time, the Board may appoint other members of such committee in addition
to, or in lieu of, the individuals holding said titles. .

         1.5      AFFILIATE shall mean (i) any corporation or other entity that
is required to be aggregated with the Company under Code Sections 414(b), (c),
(m) or (o), and (ii) any other entity in which the Company has an ownership
interest and which the Company designates as an Affiliate for purposes of the
Plan.

         1.6      BASE SALARY shall mean, with respect to a Participant for a
calendar year, the Participant's regular base salary amount paid to him during
such calendar year, plus any amounts of base salary that the Participant may
have elected to defer under the terms of any Code Section 401(k) or 125 plan or
any nonqualified deferred compensation plan maintained by the Company or an
Affiliate, but excluding bonuses, incentive compensation, expense reimbursements
and the value of any fringe benefits.

                                       1
<PAGE>

         1.7      BENEFIT COMMENCEMENT DATE shall mean, with respect to a
Participant, the first day of the month coinciding with or immediately following
the date that the Participant's employment with the Company and all Affiliates
terminates on or after the date on which he becomes eligible to receive an Early
Retirement Benefit or Normal Retirement Benefit under the Plan.

         1.8      BOARD shall mean the Board of Directors of the Company.

         1.9      CHANGE IN CONTROL shall mean any one of the following:

                  (a)      The acquisition by any person (as such term is used
in Sections 13(d) and 14(d)(2) of the Securities and Exchange Act of 1934, as
amended), together with affiliates and associates of such person, whether by
purchase, tender offer, exchange, reclassification, recapitalization, merger or
otherwise, of a sufficient number of shares of the voting securities of the
Company to first provide such person with 50% or more of the combined voting
power of the Company's then outstanding voting securities; or

                  (b)      The cessation; for any reason during any period of 2
consecutive years, of individuals who at the beginning of such period constitute
the Board, to constitute at least a majority thereof, unless the election of
each director who was not a director at the beginning of such period has been
approved in advance by a majority of the continuing directors then in office; or

                  (c)      The sale by the Company, in one transaction or a
series of related transactions, whether in liquidation, dissolution or
otherwise, of assets or earning power aggregating more than 50% of the assets or
earning power of the Company and its subsidiaries (taken as a whole) to any
other entity or entities.

         1.10     CODE shall mean the Internal Revenue Code of 1986, as amended.

         1.11     COMPANY shall mean AGCO Corporation, a Delaware corporation
with its principal place of business in Duluth, Georgia.

         1.12     DEATH BENEFIT shall mean the amount payable to a deceased
Participant's Surviving Spouse, as determined pursuant to the terms of Section
3.4.

         1.13     EARLY RETIREMENT AGE shall mean age 62.

         1.14     EARLY RETIREMENT BENEFIT shall mean the amount payable to a
Participant, as determined pursuant to Section 3.1(b).

         1.15     EFFECTIVE DATE shall mean April 1, 2000, the date as of which
this Plan shall be effective.

                                       2
<PAGE>

         1.16     ELIGIBLE EMPLOYEE shall mean any individual who, as determined
by the Board in its sole discretion, is a member of a select group of highly
compensated or key management employees of the Company.

         1.17     EMPLOYMENT COMMENCEMENT DATE shall mean, with respect to a
Participant, the date on which such Participant first performs services for the
Company or an Affiliate.

         1.18     ERISA shall mean the Employee Retirement Income Security Act
of 1974, as amended.

         1.19     FINAL EARNINGS shall mean, for a Participant, his Base Salary
for the most recent, full calendar year ending on or immediately before the date
his employment with the Company and all Affiliates terminates.

         1.20     JOINT AND 50% SURVIVOR ANNUITY shall mean a monthly retirement
benefit payable during the Participant's lifetime, with 50% of the Participant's
monthly benefit amount continuing after his death to his Surviving Spouse (if
she survives him) for such Surviving Spouse's remaining lifetime. Payments shall
cease with the payment due on the first day of the month in which occurs the
later of the Participant's death or his Surviving Spouse's death.

         1.21     NORMAL RETIREMENT AGE shall mean age 65.

         1.22     NORMAL RETIREMENT BENEFIT shall mean the amount payable to a
Participant, as determined pursuant to the terms of Section 3.1(a).

         1.23     PARTICIPANT shall mean any individual who has been admitted to
participation in the Plan pursuant to the provisions of Article II.

         1.24     PARTICIPATING COMPANY shall mean, individually, the Company or
any other Affiliate that, with the. consent of the Administrative Committee,
adopts the Plan as a participating company. A list of such members that are
participating in the Plan shall be set forth on Schedule A hereto.

         1.25     PLAN shall mean the AGCO Corporation Supplemental Executive
Retirement Plan, as contained herein and all amendments hereto.

         1.26     PLAN YEAR shall mean the 12-consecutive-month period ending on
December 31 of each year.

         1.27     SAVINGS PLAN BENEFIT shall mean the Actuarial Equivalent of a
Participant's accrued benefit attributable to employer matching contributions
and earnings thereon under the AGCO

                                       3
<PAGE>

Corporation 401(k) Savings Plan, calculated as if such benefit was payable in
the form of a single life annuity for the Participant's lifetime. The
Participant's Savings Plan Benefit shall also include the Actuarial Equivalent
of (i) all amounts attributable to employer contributions and earnings thereon
credited to the Participant's account under any nonqualified deferred
compensation plan maintained by the Company or an Affiliate, and (ii) any
benefits attributable to contributions made by the Company or any Affiliate
under any retirement plan established under the laws of any foreign country
(excluding any foreign retirement plan described in Section 1.28).

         1.28     SOCIAL SECURITY BENEFIT shall mean, for a Participant, the
maximum annual primary Social Security retirement benefit amount that, under the
law as in effect as of the Participant's Benefit Commencement Date, could be
payable to him (regardless of his actual Social Security compensation amounts)
at such date. A Participant's Social Security benefit shall also include any
retirement benefits payable to the Participant under any similar retirement
program of any foreign country.

         1.29     SURVIVING SPOUSE shall mean, with respect to a Participant,
the person who is treated as married to such Participant under the laws of the'
state in which the Participant resides. The determination of a Participant's
Surviving Spouse shall be made as of the date of such Participant's death.

         1.30     TRUST OR TRUST AGREEMENT shall mean the separate agreement or
agreements between the Company and the Trustee governing the creation of the
Trust Fund, and all amendments thereto.

         1.31     TRUSTEE shall mean the party or. parties so designated from
time to time pursuant to the terms of the Trust Agreement.

         1.32     TRUST FUND shall mean the total amount of cash and other
property held by the Trustee (or any nominee thereof) at any time under the
Trust Agreement.

         1.33     YEARS OF CREDITED SERVICE shall mean, with respect to a
Participant, the number of 12-month periods during which such Participant is
continuously employed by the Company or an Affiliate, commencing on, the later
of (A) June 20, 1990, or (B) the Participant's Employment Commencement Date
(including such periods that occur after a Participant attains Normal Retirement
Age). Years of Credited Service shall be counted in whole and partial years with
any partial year being equal to a fraction, the numerator of which is the number
of months of employment completed in the partial year, and the denominator of
which is 12.

                                       4
<PAGE>

                                   ARTICLE II
                                   ELIGIBILITY

         2.1      SELECTION OF PARTICIPANTS.

                  The Board, in its sole discretion, shall designate which
Eligible Employees shall become Participants in the Plan. The Administrative
Committee then shall set forth the name of each Participant on Schedule B
hereto. Notwithstanding anything herein to the contrary, all aspects of the
selection of Participants shall be in the sole discretion of the Board and
regardless of title, duties or any other factors, there shall be no requirement
whatsoever that any individual or group of individuals be allowed to participate
herein.

         2.2      REMOVAL FROM ACTIVE PARTICIPATION.

                  The Board may at any time remove a Participant from active
participation in the Plan, such that he shall not be credited with additional
years of Credited Service and his Accrued Benefit shall not continue to
increase.

                                       5
<PAGE>

                                   ARTICLE III
                                    BENEFITS

         3.1      BENEFIT AMOUNT.

                  (a)      NORMAL RETIREMENT BENEFIT. Upon a Participant's
termination of employment with the Company and all Affiliates on or after he
attains Normal Retirement Age and for a reason other than his death, the
Participant shall be entitled to a Normal Retirement Benefit in an amount equal
to his Accrued Benefit determined as of the date his employment so terminates.

                  (b)      EARLY RETIREMENT BENEFIT. Upon a Participant's
termination of employment with the Company and all Affiliates after he attains
Early Retirement Age (but before he attains Normal Retirement Age) and for a
reason other than his death, the Participant shall be entitled to an Early
Retirement Benefit in an amount equal to his Accrued Benefit determined as of
the date his employment so terminates, reduced using an appropriate interest
factor, as may be established by the Board from time to time, to reflect
commencement of the Participant's benefit prior to his Normal Retirement Age.
Notwithstanding the foregoing, a Participant shall be entitled to an Early
Retirement Benefit only if his termination of employment and eligibility to
receive an Early Retirement Benefit is approved by the Board; provided, however,
that a Participant who has been vested in his Accrued benefit under Section 3.3
as a result of a Change in Control shall be entitled to an Early Retirement
Benefit without regard to any such approval by the Board. .

                  (c)      TERMINATION BEFORE EARLY RETIREMENT DATE. Except as
provided in Section 3.3, upon a Participant's termination of employment with the
Company and all Affiliates before his Early Retirement Date for any reason,
neither the Participant nor his Surviving Spouse (if any) shall be entitled to
any benefit or payment under the Plan.

         3.2      PAYMENT OF BENEFIT.

                  (a)      COMMENCEMENT AND TIMING. A Participant's benefit
determined under Section 3.1 shall be paid or commenced as of his Benefit
Commencement Date. Notwithstanding the foregoing, the payment or commencement of
a Participant's benefit shall be delayed during any period in which he is
receiving salary continuation or periodic severance pay from the Company or an
Affiliate, and there shall be no adjustment in the amount of the Participant's
benefits to reflect the delayed commencement of the Participant's benefit.

                  (b)      FORM OF PAYMENT FOR RETIREMENT BENEFIT.

                           (i)      NORMAL FORM OF PAYMENT. Except as provided
in subsection (ii) hereof, a Participant's Normal Retirement Benefit or Early
Retirement Benefit shall be paid in a

                                       6
<PAGE>

maximum of 120 monthly installments, with payments to cease after the payment
due for the month in which the Participant's death occurs.

                           (ii)     OPTIONAL FORM OF PAYMENT. A Participant may
irrevocably elect, at the time he first becomes eligible to participate in the
Plan, to have his Normal Retirement Benefit or Early Retirement Benefit paid in
either of the following forms, each of. which shall be the Actuarial Equivalent
of the Participant's Normal Retirement Benefit or Early Retirement Benefit, as
applicable:

                                    (A)      Single lump sum; or

                                    (B)      Joint and 50% Survivor Annuity.

If a Participant does not elect an optional form of payment at the time he first
becomes eligible to participate in the Plan, his benefit shall be paid in the
form described in subsection (i) unless, at least 1 year before his Benefit
Commencement Date, the Participant, with the consent of the Administrative
Committee, makes a one-time election in writing to receive such benefit in an
optional form of payment permitted hereunder.

         3.3      CHANGE IN CONTROL.

                  In the event of a Change in Control of the Company, every
Participant shall become fully vested in the total amount of his Accrued Benefit
determined as of the date the Change in Control occurs. Following a Change in
Control, if a Participant terminates employment with the Company and all
Affiliates prior to his Early Retirement Date, he shall be entitled to an
immediate lump-sum payment that is the Actuarial Equivalent of his Accrued
Benefit, determined in the manner described in Section 3.1(b):

         3.4      DEATH BENEFIT.

                  In the event a Participant (i) commences to receive benefits
in the normal form provided in Section 3.2(b)(i) but dies before he has received
the entirety of his Normal Retirement Benefit or Early Retirement Benefit, or
(ii) becomes entitled to receive benefits under the Plan but dies during the
period that benefits are delayed in accordance with Section 3.2(a) while the
participant is receiving salary continuation or severance pay, then the
Participant's Surviving Spouse shall be entitled to a Death Benefit in an amount
equal to 50% of the undistributed balance of the Participant's Normal Retirement
Benefit or Early Retirement Benefit as of the date of the Participant's death.
Such Death Benefit shall be paid at the same time the Participant would have
received such benefits.

                                       7
<PAGE>

                                   ARTICLE IV
                                     CLAIMS

         4.1      CLAIMS.

                  (a)      INITIAL CLAIM. Claims for benefits under the Plan may
be filed in writing with the Administrative Committee. The Administrative
Committee shall furnish to the claimant written notice of the disposition of a
claim within 90 days after the application therefor is filed. In the event the
claim is denied, the notice of the disposition of the claim shall provide the
specific reasons for the denial, citations of the pertinent provisions of the
Plan, and, where appropriate, an explanation as to how the claimant can perfect
the claim and/or submit the claim for review.

                  (b)      APPEAL. Any Participant or Surviving Spouse who has
been denied a benefit shall be entitled, upon request to the Administrative
Committee, to appeal the denial of his claim. The claimant (or his duly
authorized representative) may review pertinent documents related to the Plan
and in the Administrative Committee's possession in order to prepare the appeal.
The request for review, together with written statement of the claimant's
position, must be filed with the Administrative Committee no later than 60 days
after receipt of the written notification of denial of a claim provided for in
subsection (a). The Administrative Committee's decision shall be made within 60
days following the filing of the request for review. If unfavorable, the notice
of decision shall explain the reasons for denial and indicate the provisions of
the Plan or other documents used to arrive at the decision.

                  (c)      SATISFACTION OF CLAIMS. Any payment to a Participant
or Surviving Spouse shall to the extent thereof be in full satisfaction of all
claims hereunder against the Administrative Committee and the Company, either of
which may require such Participant or Surviving Spouse, as a condition to such
payment, to execute a receipt and release therefor in such form as shall be
determined by the Administrative Committee or the Company. If receipt and
release is required but the Participant or Surviving Spouse (as applicable) does
not provide such receipt and release in a timely enough manner to permit a
timely distribution in accordance with the general timing of distribution
provisions in the Plan, the payment of any affected distributions) may be
delayed until the Administrative Committee or Company receives a proper receipt
and release.

                                       8
<PAGE>

                                    ARTICLE V
                             SOURCE OF FUNDS; TRUST

         5.1      SOURCE OF FUNDS.

                  Except as provided in this Section and Section 5.2, the
Company shall provide the benefits described in the Plan from the general assets
of the Company. In any event, the Company ultimately shall have the obligation
to pay all benefits due to. Participants and Surviving Spouses under the Plan.
The Company's obligation to pay benefits under the Plan constitutes a mere
promise of the Company to pay such benefits, and a Participant or Surviving
Spouse shall be and remain no more than an unsecured, general creditor of the
Company. As described in this Article, the Company may establish a Trust and pay
over funds from time to time to such Trust. To the extent that fiends in such
Trust allocable to the benefits payable under the Plan are sufficient, the Trust
assets shall be used to pay benefits under the Plan. If such Trust assets are
not sufficient to pay all benefits due under the Plan, then the Company shall
have the obligation, and the Participant or Surviving Spouse, who is due such
benefits, shall look to the Company to provide such benefits. The Administrative
Committee shall allocate the total liability to pay benefits under the Plan
among the Participating Companies in such manner and amount as the
Administrative Committee in its sole discretion deems appropriate to reflect the
benefits accrued by each Participating Company's employees.

         5.2      TRUST.

                  The Company may transfer all or any portion of the funds
necessary to fiend benefits accrued hereunder to the Trustee to be held and
administered by the Trustee pursuant to the terms of the Trust Agreement. To the
extent provided in the Trust Agreement, each transfer into the Trust Fund shall
be irrevocable as long as the Company has any liability or obligations under the
Plan to pay benefits, such that the Trust property is in no way subject to use
by the Company; provided, it is the intent of the Company that the assets held
by the Trust are and shall remain at all times subject to the claims of the
general creditors of the Company. No Participant or Surviving Spouse shall have
any interest in the assets held by the Trust or in the general assets of the
Company other than as A general, unsecured creditor. Accordingly, the Company
shall not grant a security interest in the assets held by the Trust in favor of
the Participants, Surviving Spouses or any creditor.

                                       9
<PAGE>

                                   ARTICLE VI
                           ADMINISTRATIVE COMMITTEE

         6.1      ACTION.

                  Action of the Administrative Committee may be taken with or
without a meeting of committee members; provided, action shall be taken only
upon the vote or other affirmative expression of a majority of the committee
members qualified to vote with respect to such action. If a member of the
committee is a Participant, he shall not participate in any decision which
solely affects his own benefit under the Plan. For purposes of administering the
Plan, the Administrative Committee shall choose a secretary who shall keep
minutes of the committee's proceedings and all records and documents pertaining
to the administration of the Plan. The secretary may execute any certificate or
any other written direction on behalf of the Administrative Committee.

         6.2      RIGHTS AND DUTIES.

                  The Administrative Committee shall administer the Plan and
shall have all powers necessary to accomplish that purpose, including (but not
limited to) the. following:

                  (a)      To construe, interpret and administer the Plan;

                  (b)      To make determinations required by the Plan, and to
maintain records regarding Participants and Surviving Spouses' benefits
hereunder;

                  (c)      To compute and certify to the Company the, amount and
kinds of benefits payable to Participants and Surviving. Spouses and to
determine the time and manner in which such benefits are to be paid;

                  (d)      To authorize all disbursements by the Company
pursuant to the Plan;

                  (e)      To maintain all the necessary records of the
administration of the Plan;

                  (f)      To make and publish such rules for the regulation of
the Plan as are not inconsistent with the terms hereof;

                  (g)      To delegate to other individuals or entities from
time to time the performance of any of its duties or responsibilities hereunder;

                  (h)      To hire agents, accountants, actuaries, consultants
and legal counsel to assist in operating and administering the Plan.

                                       10
<PAGE>

The Administrative Committee shall have the exclusive right to construe and to
interpret the Plan, to decide all questions of eligibility for benefits and to
determine the amount of such benefits, and its decisions on such matters are
final and conclusive on all parries.

         6.3      COMPENSATION, INDEMNITY AND LIABILITY.

                  The Administrative Committee and its members shall serve as
such without bond and without compensation for services hereunder. All expenses
of the Administrative Committee shall be paid by the Company. No member of the
committee shall be liable for any act or omission of any other member of the
committee, nor for any act or omission on his own part, excepting his own
willful misconduct. The Company shall indemnify and hold harmless the
Administrative Committee and each member thereof against any and all expenses
and liabilities, including reasonable legal fees and expenses, arising out of
his membership on the committee, excepting only expenses and liabilities arising
out of his own willful misconduct.

         6.4      TAXES.

                  If the whole or any part of any Participant's or Surviving
Spouse's benefit hereunder shall become subject to any estate, inheritance,
income or other tax which the Company shall be required to pay or withhold, the
Company shall have the full power and authority to withhold and pay such tax out
of any movies or other property in its hand for the account of the Participant
or Surviving Spouse whose interests hereunder are so affected. Prior to making
any payment, the Company may require such releases or other documents from any
lawful taxing authority as it shall deem necessary.

                                       11
<PAGE>

                                   ARTICLE VII
                            AMENDMENT AND TERMINATION

         7.1      AMENDMENTS.

                  The Board shall have the right to amend the Plan .in whole or
in part at any time and from time to time. An amendment to the Plan may modify
its terms in any respect whatsoever (including freezing future benefit
accruals); provided, no amendment may decrease the level of a Participant's
benefit or adversely affect a Participant's or Surviving Spouse's rights to
benefits that already have accrued.

         7.2      TERMINATION OF PLAN.

                  The Board shall each have the right to terminate the Plan at
any time, for any reason. If the Plan is terminated, each. Participant's benefit
under the Plan will be frozen and will be paid under the condition, at the time
and in the form, specified under the terms of the Plan. Termination of the Plan
shall be binding on all Participants and Surviving Spouses.

                                       12
<PAGE>

                                  ARTICLE VIII
                                  MISCELLANEOUS

         8.1      TAXATION.

                  It is the intention of the Company that the benefits payable
hereunder shall not be deductible by the Company nor taxable for federal income
tax purposes to Participants and Surviving Spouses until such benefits are paid
by the Company, or by the Trust, as the case may be, to such .Participants and
Surviving Spouses. When such benefits are so paid, it is the intention of the
Company that they shall be deductible by the Company under Code Section 162.

         8.2      NO EMPLOYMENT CONTRACT.

                  Nothing herein contained is intended to be nor shall be
construed as constituting a contract arrangement between the Company and any
Participant to the effect that the Participant will be employed by the Company
for any specific period of time.

         8.3      HEADINGS.

                  The headings of the various articles and sections in the Plan
are solely for convenience and shall not be relied upon in construing any
provisions hereof. Any reference to a section shall refer to a section of the
Plan unless specified otherwise.

         8.4      GENDER AND NUMBER.

                  Use of any gender in the Plan will be deemed to include all
genders when appropriate, and use of the singular number will be deemed to
include the plural when appropriate, and vice versa in each instance.

         8.5      ASSIGNMENT OF BENEFITS.

                  The right of a Participant or any other person to receive
payments under the Plan shall not be assigned, transferred, pledged or
encumbered, except by will or by the laws of descent and distribution and then
only to the extent permitted under the terms of the Plan.

         8.6      LEGALLY INCOMPETENT.

                  The Administrative Committee, in its sole discretion, may
direct that payment be made to an incompetent or disabled person, whether
because of minority or mental or physical disability, to the guardian of such
person or to the person having custody of such person, without

                                       13
<PAGE>

further liability on the part of the Administrative Committee, the Company or
any Affiliate for the amount of such payment to the person on whose account such
payment is made.

         8.7      GOVERNING LAW.

                  The Plan shall be construed, administered and governed in all
respects in accordance with applicable federal law and, to the extent not
preempted by federal law, in accordance with the laws of the State of Georgia.
If any provisions of this instrument shall be held by a court of competent
jurisdiction to be invalid or unenforceable, the remaining provisions hereof
shall continue to be fully effective.

         IN WITNESS WHEREOF, the Company has caused the Plan to be executed by
its duly authorized officer as of the day arid year first above written.

                                AGCO CORPORATION

                                  By: /s/ R. J. Ratliff
                                     ------------------------------------------
                                     Title: Chairman
                                            -----------------------------------

                                       14
<PAGE>

                                   SCHEDULE A

                            PARTICIPATING COMPANIES

PARTICIPATING COMPANY                        EFFECTIVE DATE

AGCO Corporation                             1 April 2000

                                       15<PAGE>

                                                                  EXHIBIT 10.33

[AMGEN LOG]                                              AGREEMENT NO. 20010240
-------------------------------------------------------------------------------

This agreement ("Agreement"), together with all appendices attached hereto and
incorporated herein by this reference, between Amgen Inc. ("Amgen") and Renal
Care Group, Inc., ("RCG"), sets forth the terms and conditions for the purchase
of EPOGEN(R)(Epoetin alfa) by RCG for the exclusive treatment of dialysis
patients.

1.       TERM OF AGREEMENT. The "Term" of this Agreement shall be defined as
         January 1, 2002 ("Commencement Date") through December 31, 2002
         ("Termination Date").

2.       DIALYSIS CENTER AFFILIATES. RCG must provide Amgen with a complete list
         of its dialysis center affiliates ("Affiliates") on or before the date
         this Agreement is executed by RCG. Only those Affiliates approved by
         Amgen and referenced in Appendix B hereto will be eligible to
         participate under this Agreement. Modifications to the dialysis center
         Affiliates included in Appendix B may be made pursuant to the request
         of RCG's corporate headquarters and are subject to approval and
         acknowledgment by Amgen in writing. Notification of proposed changes to
         the list of Affiliates must be provided by RCG to Amgen in writing at
         least 30 days before the effective date of the proposed change. Amgen
         reserves the right to accept, reject, or immediately terminate any
         Affiliates with regard to participation in this Agreement.

3.       OWN USE. RCG hereby certifies that EPOGEN(R)purchased hereunder shall
         be for RCG's "own use", for the exclusive treatment of dialysis
         patients.

4.       AUTHORIZED WHOLESALERS. On or before the date RCG executes this
         Agreement, RCG must provide Amgen with a complete list of its current
         wholesalers, from which RCG intends to purchase EPOGEN(R). Wholesalers
         so designated by RCG and approved by Amgen will be deemed "Authorized
         Wholesalers" for the purposes of this Agreement. A current listing of
         RCG's Authorized Wholesalers shall be included in Appendix B.
         Notification of proposed changes to the list of Authorized Wholesalers
         must be provided to Amgen in writing at least 30 days before the
         effective date of the proposed change. Amgen reserves the right to
         accept, reject, or immediately terminate any wholesaler with regard to
         participation in this Agreement. In the event Amgen terminates any
         Authorized Wholesaler from which RCG is purchasing EPOGEN(R), Amgen
         will work with RCG to identify other possible Authorized Wholesalers
         from which RCG may purchase EPOGEN(R). In the event that RCG is unable
         to identify another Authorized Wholesaler from which RCG may purchase
         EPOGEN(R), and subject to receipt and approval of an *. RCG agrees to
         require all Authorized Wholesalers to submit product sales information
         directly to Amgen and to a third-party sales reporting organization
         designated by Amgen.

5.       QUALIFIED PURCHASES. Only EPOGEN(R)purchased under this Agreement by
         RCG through *.

6.       COMMITMENT TO PURCHASE. RCG agrees to purchase EPOGEN(R) for all of its
         dialysis use requirements for recombinant human erythropoietin. RCG may
         purchase another brand of recombinant human erythropoietin for its
         dialysis use requirements only for the time, and only to the extent,
         that Amgen has notified RCG's corporate headquarters in writing that
         Amgen cannot supply EPOGEN(R) within and for the time period reasonably
         required by RCG.

7.       CONFIDENTIALITY. Both Amgen and RCG agree that this Agreement
         represents and contains confidential information which shall not be
         disclosed to any third party, or otherwise made public, without prior
         written authorization of the other party, except where such disclosure
         is contemplated hereunder or required by law, and then only upon prior
         written notification to the other party.

* Omitted information is the subject of a request for confidential treatment
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been
filed separately with the Securities and Exchange Commission.

AGREEMENT NO. 20010240               - 1 -                         Ver. 10/8/01

<PAGE>
                                              AGREEMENT NO. 20010240 (CONTINUED)
================================================================================

8.       DISCOUNTS. RCG may qualify for discounts and incentives in accordance
         with the schedules and terms set forth in Appendix A. Discounts in
         arrears will be paid in the form of a check payable to RCG's corporate
         headquarters. Discounts in arrears will be calculated in accordance
         with Amgen's discount calculation policies based on * using the * as
         the calculation price, except as otherwise provided hereunder. Upon
         vesting, Amgen will use its best efforts to make such discounts
         available within * after receipt by Amgen of data, in a form reasonably
         acceptable to Amgen, detailing all * during the applicable period.
         Payment amounts, as calculated by Amgen, must equal or exceed $100.00
         for the applicable period to qualify. Subject to the section entitled
         "Breach of Agreement", in the event that Amgen is notified in writing
         that RCG, and/or any Affiliates are acquired by another entity or a
         change of control otherwise occurs with respect to RCG or an Affiliate,
         any discounts which may have been earned hereunder shall be paid in the
         form of a check payable to RCG's or the Affiliate's corporate
         headquarters subject to the conditions described herein. If any
         Affiliates are added to or deleted from this Agreement during any of
         the periods used for comparison, for any of the discounts paid in
         arrears contained herein, Amgen reserves the right in its sole and
         reasonable discretion to appropriately adjust RCG's discounts for the
         relevant periods, by including or excluding any purchases made by those
         Affiliates during any of those periods.

9.       TREATMENT OF DISCOUNTS. RCG agrees that it will properly disclose and
         account for any discount or other reduction in price earned hereunder,
         in whatever form, (i.e. pricing, discount, or incentive) in a way that
         complies with all applicable federal, state, and local laws and
         regulations, including without limitation, Section 1128B(b) of the
         Social Security Act and its implementing regulations. Section 1128B(b)
         requires that a provider of services will properly disclose and
         appropriately reflect the value of any discount or other reduction in
         price earned in the costs claimed or charges made by the provider under
         a federal health care program, as that term is defined in Section
         1128B(f). RCG also agrees that it will (a) claim the benefit of such
         discount received, in whatever form, in the fiscal year in which such
         discount was earned or the year after, (b) fully and accurately report
         the value of such discount in any cost reports filed under Title XVIII
         or Title XIX of the Social Security Act, or a state health care
         program, and (c) provide, upon request by the U.S. Department of Health
         and Human Services or a state agency or any other federally funded
         state health care program, the information furnished by Amgen
         concerning the amount or value of such discount. RCG's corporate
         headquarters agrees that it will advise all Affiliates, in writing, of
         any discount received by RCG's corporate headquarters hereunder with
         respect to purchases made by such Affiliates and that said Affiliates
         will account for any such discount in accordance with the above stated
         requirements.

10.      DATA COLLECTION. RCG agrees that all data to be provided to Amgen
         pursuant to this Agreement, shall be in a form that does not disclose
         the identity or name of any patient or other patient-identifying
         information such as address, telephone number, or social security
         number. RCG acknowledges that the data to be supplied to Amgen pursuant
         to this Agreement shall be used to support verification of the
         discounts and incentives referenced herein, as well as for
         Amgen-sponsored research concerning the role of EPOGEN(R) in improving
         treatment outcomes and quality of life of dialysis patients. RCG shall
         consistently use a unique alpha-numeric code (which shall not be the
         same as the patient's social security number) as a "case identifier" to
         track the care rendered to each individual patient over time, and such
         case identifier shall be included in the data provided to Amgen. The
         key or list matching patient identities to their unique case
         identifiers shall not be provided to Amgen personnel. In furtherance of
         Amgen research, RCG may agree from time to time to use its key to
         update the patient care data by linking it with information concerning
         health outcomes, quality of life, and other pertinent data that may
         become available to Amgen from other sources. Any such linking of data
         sources shall not provide the identity of any patient to Amgen. Amgen
         agrees that it will maintain data supplied under this Agreement in
         confidence and that it will not use such data to identify or contact
         any patient. No reports by Amgen concerning analyses of the data or the
         results of such research shall disclose the identity of any patient.

11.      BREACH OF AGREEMENT. If either party materially breaches this
         Agreement, then the other party may terminate this Agreement for breach
         upon 30 days' advance written notice. In addition, in the event that
         RCG materially breaches any provision of this Agreement, Amgen shall
         have no obligation to continue to offer the terms described herein or
         pay any further discounts to RCG.

12.      GOVERNING LAW. This Agreement shall be governed by the laws of the
         State of California and the parties hereby submit to the jurisdiction
         of the California courts, both state and federal.

* Omitted information is the subject of a request for confidential treatment
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been
filed separately with the Securities and Exchange Commission.

AGREEMENT NO. 20010240               - 2 -                         Ver. 10/8/01

<PAGE>
                                              AGREEMENT NO. 20010240 (CONTINUED)
================================================================================

13.      WARRANTIES. Each party represents and warrants to the other that this
         Agreement (a) has been duly authorized, executed, and delivered by it,
         (b) constitutes a valid, legal, and binding agreement enforceable
         against it in accordance with the terms contained herein, and (c) does
         not conflict with or violate any of its other contractual obligations,
         expressed or implied, to which it is a party or by which it may be
         bound. The party executing this Agreement on behalf of RCG specifically
         warrants and represents to Amgen that he is authorized to execute this
         Agreement on behalf of and has the power to bind RCG and the Affiliates
         to the terms set forth in this Agreement. The party executing this
         Agreement on behalf of Amgen specifically warrants and represents to
         RCG that he is authorized to execute this Agreement on behalf of and
         has the power to bind Amgen to the terms set forth in this Agreement.

14.      NOTICES. Any notice or other communication required or permitted
         hereunder shall be in writing and shall be deemed given or made when
         delivered in person or when sent to the other party by first class
         mail, nationally recognized overnight delivery service or other means
         of written communication at the respective party's current address or
         at such other address as the party shall have furnished to the other in
         accordance with this provision.

15.      COMPLIANCE WITH HEALTH CARE PRICING AND PATIENT PRIVACY LEGISLATION AND
         STATUTES. (a) Notwithstanding anything contained herein to the
         contrary, at any time following the enactment of any federal, state, or
         local law or regulation that in any manner reforms, modifies, alters,
         restricts, or otherwise adversely affects the pricing of or
         reimbursement available for EPOGEN(R), Amgen may, in its sole
         discretion, upon 30 days' notice (i) terminate this Agreement, or (ii)
         exclude any Affiliates from participating in this Agreement unless such
         Affiliate(s) certifies in writing that they are, or will be, exempt
         from the provisions thereunder. Additionally, in order to assure
         compliance with any existing federal, state or local statute,
         regulation or ordinance, Amgen reserves the right to exclude any
         Affiliates from the pricing, discount, and incentive provisions of this
         Agreement if, in the opinion of Amgen's legal counsel such exclusion is
         necessary to assure such compliance.

         (b) Notwithstanding anything contained herein to the contrary, at any
         time following the enactment of any federal, state, or local law or
         regulation relating to patient privacy of medical records that in any
         manner reforms, modifies, alters, restricts, or otherwise affects any
         of the data received or to be received in connection with any of the
         incentives contemplated under this Agreement, either party may, in its
         discretion, upon 30 days' notice, seek to modify this Agreement with
         respect to the affected incentive. RCG and Amgen shall meet and in good
         faith seek to mutually agree to modify this Agreement to accommodate
         any such change in law or regulation, with the intent to, if possible,
         retain the essential * structure of the affected incentive. If the
         parties, after reasonable time, are unable to agree upon a
         modification, Amgen shall be entitled to terminate the affected
         incentive upon 30 days' notice, provided that if Amgen so terminates an
         incentive, RCG shall be entitled to terminate this Agreement upon 30
         days' notice.

16.      FORCE MAJEURE. Neither party will be liable for delays in performance
         or nonperformance of this Agreement or any covenant contained herein if
         such delay or nonperformance is a result of Acts of God, civil or
         military authority, civil disobedience, epidemics, war, failure of
         carriers to furnish transportation, strike, lockout or other labor
         disturbances, inability to obtain material or equipment, or any other
         cause of like or different nature beyond the control of such party.

17.      MISCELLANEOUS. No modification of this Agreement will be effective
         unless made in writing and executed by a duly authorized representative
         of each party, except as otherwise provided hereunder. Neither party
         may assign this Agreement to a third party without the prior written
         consent of the other party. This Agreement may be executed in one or
         more counterparts, each of which is deemed to be an original but all of
         which taken together constitutes one and the same agreement.

   * Omitted information is the subject of a request for confidential treatment
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been
filed separately with the Securities and Exchange Commission.

AGREEMENT NO. 20010240               - 3 -                        Ver. 10/8/01

<PAGE>
                                             AGREEMENT NO. 20010240 (CONTINUED)
===============================================================================

18.      ENTIRE AGREEMENT. This Agreement constitutes the entire understanding
         between the parties and supersedes all prior written or oral proposals,
         agreements, or commitments pertaining to the subject matter herein.

Please retain one fully executed original for your records and return the other
fully executed original to Amgen.

THE PARTIES EXECUTED THIS AMENDMENT AS OF THE DATES SET FORTH BELOW.

AMGEN INC.                                 RENAL CARE GROUP, INC.

Signature:                                 Signature:
              ---------------------                      ----------------------
Print Name:                                Print Name:
              ---------------------                      ----------------------
Print Title:                               Print Title:
              ---------------------                      ----------------------
Date:                                      Date:
              ---------------------                      ----------------------

AGREEMENT NO. 20010240               - 4 -                         Ver. 10/8/01

<PAGE>
                                             AGREEMENT NO. 20010240 (CONTINUED)
===============================================================================

                APPENDIX A: DISCOUNT PRICING, SCHEDULE, AND TERMS

1.       PRICING. Throughout the Term of this Agreement (January 1, 2002 -
         December 31, 2002), RCG may purchase EPOGEN(R) through * at an *, which
         shall be equal * in effect on the date of *. Amgen reserves the right
         to change the * at any time, which change shall * RCG during the Term
         of this Agreement. Resulting prices do not include *. All discounts
         earned in arrears during the Term of the Agreement shall be calculated
         based *.

2.       *. RCG may qualify for a * provided it meets the criteria described
         below in this section. * is designed to improve patient outcomes by
         encouraging the * which recommends *.

         A.       REQUIREMENTS: In order to qualify for *, RCG's aggregate * of
                  EPOGEN(R) by all Affiliates as listed on Appendix B on the
                  Commencement Date of this Agreement must equal or exceed * of
                  the aggregate * of EPOGEN(R) by those same Affiliates for the
                  *. In addition, no more than * may have * during each *
                  quarter of the Term. If either of these criteria is not met
                  during any given * of the Term, RCG will not qualify for the *
                  during that *. Failure of RCG to qualify for the * during a
                  particular *.

                  In order to participate in *, RCG must provide the following
                  to Amgen or to a data collection vendor specified by Amgen, on
                  *, and * after the *:

         i)       all * for each dialysis patient, the date of each test, and a
                  consistent, unique, alpha-numeric identifier (sufficient
                  consistently to track an individual patient without in any way
                  disclosing the identity of the patient), along with the name,
                  address and phone number of the particular Affiliate at which
                  each patient received treatment (collectively the "Data"). To
                  the extent permitted by applicable law, Amgen may utilize the
                  Data for any purpose, and reserves the right to audit all
                  Data. Under no circumstances should the Data include any
                  patient identifiable information including, without
                  limitation, name, complete social security number, address or
                  birth date. The identity of the account submitting the Data
                  and any association with the Data will remain confidential.
                  The * must be derived from * taken immediately before dialysis
                  treatment using any * testing method (*), must be reported to
                  the * and must be submitted * in a format reasonably
                  acceptable to Amgen. Hand written reports are not acceptable;
                  electronic submission of the Data is preferred, and

          APPENDIX A: DISCOUNT PRICING, SCHEDULE, AND TERMS (CONTINUED)

         ii)      a properly executed "Certification Letter", a sample of which
                  is attached hereto as Exhibit #1, that will be provided to
                  RCG's corporate headquarters, unless otherwise requested,
                  after this Agreement is executed by both parties.

         B.       CALCULATION: Assuming RCG has fulfilled all requirements as
                  described in Section 2(a) above, RCG's * will be calculated as
                  follows:

                  The * for each dialysis patient will be based upon the average
                  of all * gathered for each patient during * of the Term. The *
                  of all dialysis patients with *, will be determined by
                  dividing the total number of dialysis patients with *. * will
                  be calculated based on RCG's overall performance in accordance
                  with Amgen's discount calculation policies.

         C.       PAYMENT: The * will be calculated on a * and paid to RCG's
                  corporate headquarters, except as otherwise provided
                  hereunder. Payment is contingent upon receipt by Amgen of the
                  "Certification Letter" and * for the *. If Data is received
                  more than * after *, the total * of EPOGEN(R)attributable to
                  RCG during * for that *. Notwithstanding the foregoing, if
                  Amgen receives all required Data from * of all Affiliates
                  within the time frame

   * Omitted information is the subject of a request for confidential treatment
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been
filed separately with the Securities and Exchange Commission.

AGREEMENT NO. 20010240               - 5 -                         Ver. 10/8/01
<PAGE>
                                             AGREEMENT NO. 20010240 (CONTINUED)
===============================================================================

                  referenced above for *, the total * of EPOGEN(R)attributable
                  to RCG during *, will be included in the calculation of * for
                  that *. However, if Amgen determines that any Affiliate is
                  consistently not submitting the required Data, Amgen reserves
                  the right in its sole discretion to exclude such Affiliate's *
                  of EPOGEN(R)from the calculation * for any *. * payments will
                  be based upon the Data received from the *, and will equal a
                  percentage of RCG's total * of EPOGEN(R) during that *
                  (exclusive of any * of EPOGEN(R)made by RCG or any Affiliate
                  not meeting the Data submission requirements described above)
                  as governed by the * schedule listed below. Notwithstanding
                  the foregoing, payment for any period during the Term that is
                  not equivalent to a *, will be based *. If the EPOGEN(R)* or
                  the *, then Amgen and RCG agree *. In addition, at the end of
                  the Term of this Agreement, Amgen will conduct an analysis to
                  determine if RCG has achieved the *. If at the end of the Term
                  * then Amgen *. However, if at the end of the Term, *.

          APPENDIX A: DISCOUNT PRICING, SCHEDULE, AND TERMS (CONTINUED)

          * ALL DIALYSIS PATIENTS                                 *
                                   WITH *                INCENTIVE PERCENTAGE

*
         PLEASE DIRECT YOUR ATTENTION TO THE EPOGEN(R) PACKAGE INSERT

*

         D.       VESTING: RCG's * will vest at the *.

         E.       * SUBMISSION: In the event RCG adds any Affiliates still
                  submitting Data based on * to this Agreement, such Affiliates'
                  * of EPOGEN(R), for the * in which they were added, shall be
                  included in the calculation of * payment. Amgen will accept
                  the *. In order for such added Affiliates' * EPOGEN(R) to be
                  included in all subsequent * payment calculations, such
                  Affiliate must submit *.

3.       PARTNER INFORMATION PROGRAM *. RCG shall be eligible to receive * if
         certain data elements are transmitted to Amgen electronically. The *
         will be calculated as a percentage of the * of EPOGEN(R) attributable
         to RCG during *. In order to qualify for the *, the following * must be
         submitted to Amgen by all Affiliates *. Such * must be submitted, on a
         *, and *. If such * is received * within a given *, the total * of
         EPOGEN(R)attributable to RCG * from the calculation of the * for that
         *. Notwithstanding the foregoing, if Amgen receives all required *
         within the time frame referenced above for any * the total * of
         EPOGEN(R)attributable to RCG during such * will be * discount for that
         *. However, if Amgen determines that any Affiliate is consistently *,
         Amgen and RCG will work collaboratively in resolving such
         inconsistencies. Amgen reserves the right, in its sole discretion, to
         exclude any such non-reporting Affiliate's * EPOGEN(R)from the
         calculation of the * for any relevant * will vest on the last day of
         the corresponding calendar *, and will be paid * thereafter.

   * Omitted information is the subject of a request for confidential treatment
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been
filed separately with the Securities and Exchange Commission.

AGREEMENT NO. 20010240               - 6 -                         Ver. 10/8/01
<PAGE>
                                             AGREEMENT NO. 20010240 (CONTINUED)
===============================================================================

          APPENDIX A: DISCOUNT PRICING, SCHEDULE, AND TERMS (CONTINUED)

4.   *.  RCG may qualify for * as described below.

         A.       CALCULATION: RCG's * will be calculated in accordance with the
                  following formula. *

         B.       VESTING: RCG's * will vest * and the * amount earned.

   * Omitted information is the subject of a request for confidential treatment
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been
filed separately with the Securities and Exchange Commission.

AGREEMENT NO. 20010240               - 7 -                         Ver. 10/8/01
<PAGE>
                                             AGREEMENT NO. 20010240 (CONTINUED)
===============================================================================

5.   *.

                       APPENDIX B: LIST OF RCG AFFILIATES

                                 To be Attached

TO ENSURE YOU RECEIVE THE APPROPRIATE DISCOUNT, IT IS IMPORTANT THAT WE HAVE
YOUR CURRENT LIST OF AUTHORIZED WHOLESALERS. THE FOLLOWING LIST REPRESENTS THE
WHOLESALERS AMGEN CURRENTLY HAS ASSOCIATED WITH YOUR CONTRACT. PLEASE UPDATE THE
LIST BY ADDING OR DELETING WHOLESALERS AS NECESSARY.

Metro Medical Supply Inc.
3332 Powell Avenue
Nashville, TN  37204

Henry Schein, Inc.
135 Duryea Road
Nelville, NY  11747

Priority HealthCare Corporation
285 West Central Parkway, Suite 1704
Altamonte Springs, FL  32714

   * Omitted information is the subject of a request for confidential treatment
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been
filed separately with the Securities and Exchange Commission.

AGREEMENT NO. 20010240               - 8 -                         Ver. 10/8/01
<PAGE>
                                             AGREEMENT NO. 20010240 (CONTINUED)
===============================================================================

                                                                      EXHIBIT #1

                           SAMPLE CERTIFICATION LETTER

Month X, 2001

FSDC Legal Name
Street Address
City, ST  Zip

RE:  EPOGEN(R) (Epoetin alfa) Agreement No. 9XXXXX

Dear ____________:

Thank you for your participation in the *. In order for us to enroll you, we
require that a duly authorized representative of your organization sign the
certification below.

Upon receipt of this executed document, we will calculate the value of your *.
If we do not receive the executed certification, we cannot provide you with this
*.

If you have any questions regarding this letter please contact me at *. Thank
you for your assistance in returning this certification.

Sincerely,

*

CERTIFICATION:

   * Omitted information is the subject of a request for confidential treatment
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been
filed separately with the Securities and Exchange Commission.

AGREEMENT NO. 20010240               - 9 -                         Ver. 10/8/01
<PAGE>
                                             AGREEMENT NO. 20010240 (CONTINUED)
===============================================================================

On behalf of FSDC Legal Name and all eligible Affiliates participating in the *
under Agreement No. XXXXXX, the undersigned hereby certifies that the * required
to be submitted (herein referred to as *), for each eligible Affiliate during
the term of this Agreement includes the required * from all dialysis patients
from each such Affiliate, *. The party executing this document also represents
and warrants that it (i) has no reason to believe that the submitted * is
incorrect, and (ii) is authorized to make this certification on behalf of all
eligible Affiliates submitting *.

FSDC LEGAL NAME

Signature:
          -------------------------------------
Print Name:
          -------------------------------------
Print Title:
          -------------------------------------
Date:
     ------------------------------------------

   * Omitted information is the subject of a request for confidential treatment
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been
filed separately with the Securities and Exchange Commission.

                                     - 10 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}]]